Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Pacific Biosciences of California	Coherent	Berkeley Lights	Bruker	Quanterix
Symbol	NASDAQ:PACB	NASDAQ:COHR	NASDAQ:BLI	NASDAQ:BRKR	NASDAQ:QTRX
Price Information
Current Price	$31.53	$268.04	$47.93	$67.65	$61.09
52 Week Range	Buy	Hold	Buy	Hold	Buy
MarketRank™
Overall Score	1.6	1.5	1.4	1.9	1.4
Analysis Score	3.4	1.2	3.4	1.1	2.5
Community Score	2.8	2.6	2.9	2.4	2.3
Dividend Score	0.0	0.0	0.0	1.7	0.0
Ownership Score	1.7	1.7	0.0	1.7	1.7
Earnings & Valuation Score	0.0	1.9	0.6	2.5	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Buy
Consensus Price Target	$43.50	$169.00	$95.00	$55.50	$71.67
% Upside from Price Target	37.96% upside	-36.95% downside	98.21% upside	-17.96% downside	17.31% upside
Trade Information
Market Cap	$6.09 billion	$6.56 billion	$3.18 billion	$10.25 billion	$2.22 billion
Beta	1.32	1.54	N/A	1.29	1.71
Average Volume	4,758,249	565,336	1,132,851	473,592	438,231
Sales & Book Value
Annual Revenue	$90.89 million	$1.23 billion	N/A	$2.07 billion	$56.73 million
Price / Sales	66.99	5.34	N/A	4.95	39.06
Cashflow	N/A	$33.30 per share	N/A	$2.39 per share	N/A
Price / Cash	N/A	8.05	N/A	28.29	N/A
Book Value	$0.36 per share	$38.23 per share	N/A	$5.96 per share	$4.59 per share
Price / Book	87.58	7.01	N/A	11.35	13.31
Profitability
Net Income	$-84,130,000.00	$-414,140,000.00	N/A	$197.20 million	$-40,800,000.00
EPS	($0.55)	$1.44	N/A	$1.57	($1.63)
Trailing P/E Ratio	N/A	N/A	0.00	66.32	N/A
Forward P/E Ratio	N/A	38.79	N/A	39.33	N/A
P/E Growth	N/A	N/A	N/A	7.11	N/A
Net Margins	-57.25%	-33.70%	N/A	8.04%	-41.69%
Return on Equity (ROE)	-101.30%	3.41%	N/A	21.78%	-22.37%
Return on Assets (ROA)	-32.33%	1.81%	N/A	6.99%	-16.55%
Dividend
Annual Payout	N/A	N/A	N/A	$0.16	N/A
Dividend Yield	N/A	N/A	N/A	0.24%	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	10.19%	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	1 Years	N/A
Debt
Debt-to-Equity Ratio	N/A	0.44%	0.05%	0.86%	0.01%
Current Ratio	1.84%	4.52%	11.41%	2.67%	7.65%
Quick Ratio	1.72%	2.93%	10.87%	1.65%	7.18%
Ownership Information
Institutional Ownership Percentage	84.85%	91.82%	26.96%	65.89%	71.60%
Insider Ownership Percentage	11.60%	0.62%	N/A	26.80%	25.40%
Miscellaneous
Employees	412	4,875	230	7,400	314
Shares Outstanding	193.10 million	24.46 million	66.28 million	151.57 million	36.27 million
Next Earnings Date	4/29/2021 (Confirmed)	5/26/2021 (Estimated)	5/11/2021 (Confirmed)	5/5/2021 (Confirmed)	5/4/2021 (Estimated)
Optionable	Optionable	Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Insider Selling: Quanterix Co. (NASDAQ:QTRX) SVP Sells 1,667 Shares of Stock americanbankingnews.com - April 15 at 7:40 PM
	Global Preventive Medicine Market 2021 Overview, Opportunities, In-Depth Analysis by 2025 : Novo Nordisk, Eli Lilly, Preventive Medical Health Care, Cancer Prevention Pharmaceuticals, Quanterix, Phoenix Medicine, US Preventive Medicine - Los Hijos de la Malinche loshijosdelamalinche.com - April 15 at 8:26 AM
	Powering Precision Health Founder Leads Conversation at the Precision Medicine Leaders Summit on Disrupting Precision Health with Next-Generation Proteomics - Business Wire businesswire.com - April 12 at 6:01 PM
	Global Biomarker Detection Systems Market Latest Analysis 2020 – Thermo Fisher Scientific, Quanterix, Agilent Technologies – ROUGH Magazine - ROUGH Magazine rough.asia - April 12 at 1:00 PM
	-$0.32 EPS Expected for Quanterix Co. (NASDAQ:QTRX) This Quarter americanbankingnews.com - April 10 at 12:12 PM
	QUANTERIX CORP : Change in Directors or Principal Officers (form 8-K) - marketscreener.com marketscreener.com - April 9 at 7:30 PM
	A List of 7 Proteomics Stocks For Investing in Proteins - Nanalyze nanalyze.com - April 8 at 12:56 PM
	Vizgen Raises $37M in Series B Financing - GenomeWeb genomeweb.com - April 8 at 12:35 AM
	Do Traders Think Quanterix Corp (QTRX) Can Keep Climbing Tuesday? - InvestorsObserver investorsobserver.com - April 6 at 5:16 PM
	Quanterix (NASDAQ:QTRX) Trading Up 7.2% americanbankingnews.com - April 6 at 1:02 PM
	Insider Selling: Quanterix Co. (NASDAQ:QTRX) General Counsel Sells 201 Shares of Stock americanbankingnews.com - April 5 at 5:50 PM
	Quanterix Co. (NASDAQ:QTRX) CEO E Kevin Hrusovsky Sells 3,432 Shares americanbankingnews.com - April 5 at 4:46 PM
	Index Falls Again in March, Led by 29 Percent Decline in Adaptive Biotech Stock \| GenomeWeb - GenomeWeb genomeweb.com - April 2 at 12:55 AM
	Neurological Biomarkers Market Business Growth Statistics and Key Players Insights By Quanterix Corp - PharmiWeb.com pharmiweb.com - April 1 at 9:54 AM
	Quanterix (NASDAQ:QTRX) Shares Gap Up to $54.66 americanbankingnews.com - March 31 at 11:00 AM
	Quanterix (NASDAQ:QTRX) Rating Increased to Hold at Zacks Investment Research marketbeat.com - March 31 at 3:42 AM
	Quanterix' Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples - Business Wire businesswire.com - March 26 at 6:21 PM
	Quanterix’ Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples finance.yahoo.com - March 26 at 8:17 AM
	Assessment of the Alzheimers Diagnostic Test Market, 2021-2025: QUANTERIX,F. HOFFMANN-LA ROCHE LTD – The Market Eagle - The Market Eagle themarketeagle.com - March 25 at 3:18 PM
	Quanterix (NASDAQ:QTRX) Shares Gap Down to $60.33 americanbankingnews.com - March 24 at 11:54 AM
	Quanterix : Ultrasensitive quantification of plasma biomarkers is shaping the future of care for Alzheimer's disease - Marketscreener.com marketscreener.com - March 22 at 3:09 PM
	Quanterix' Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson's & Alzheimer's Disease (AD/PDTM 2021) - Business Wire businesswire.com - March 17 at 7:45 PM
	Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021) finance.yahoo.com - March 17 at 7:45 PM
	How Will the Market React to Quanterix Corp (QTRX) Stock Getting a Bullish Rating - InvestorsObserver investorsobserver.com - March 12 at 9:39 PM
	Do Analysts Agree Monday on Quanterix Corp (QTRX) Stock's Target Price? - InvestorsObserver investorsobserver.com - March 9 at 12:34 AM
	(3/7/2021) QTRX Stock Has Strong Chance Of A Rise Over The Next Month After Declining 18% In The Last 5 Days. - Trefis trefis.com - March 8 at 2:28 PM

Date	Company	Brokerage	Action
2/12/2021	Pacific Biosciences of California	Morgan Stanley	Boost Price Target
2/11/2021	Pacific Biosciences of California	Cantor Fitzgerald	Boost Price Target
2/11/2021	Pacific Biosciences of California	Piper Sandler	Upgrade
10/2/2020	Pacific Biosciences of California	JPMorgan Chase & Co.	Upgrade
12/18/2019	Pacific Biosciences of California	Piper Jaffray Companies	Reiterated Rating
4/2/2019	Pacific Biosciences of California	Stephens	Downgrade
1/4/2019	Pacific Biosciences of California	Cowen	Downgrade
2/11/2021	Coherent	Benchmark	Downgrade
1/21/2021	Coherent	Berenberg Bank	Downgrade
1/20/2021	Coherent	Barclays	Upgrade
11/12/2020	Coherent	Longbow Research	Downgrade
11/11/2020	Coherent	Stifel Nicolaus	Downgrade
9/14/2020	Coherent	Vertical Research	Upgrade
8/5/2020	Coherent	Needham & Company LLC	Reiterated Rating
5/29/2020	Coherent	Susquehanna Bancshares	Reiterated Rating
4/24/2020	Coherent	The Goldman Sachs Group	Upgrade
11/10/2020	Berkeley Lights	KeyCorp	Initiated Coverage
8/11/2020	Berkeley Lights	William Blair	Reiterated Rating
2/17/2021	Bruker	Citigroup	Boost Price Target
2/5/2021	Bruker	Wells Fargo & Company	Downgrade
1/27/2021	Bruker	SVB Leerink	Boost Price Target
12/17/2020	Bruker	BTIG Research	Boost Price Target
12/16/2020	Bruker	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
12/16/2020	Bruker	Smith Barney Citigroup	Boost Price Target
11/16/2020	Bruker	Wolfe Research	Upgrade
7/20/2020	Bruker	Bank of America	Boost Price Target
5/1/2020	Bruker	Cleveland Research	Downgrade
4/28/2020	Bruker	UBS Group	Lower Price Target
3/3/2021	Quanterix	Canaccord Genuity	Boost Price Target

(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources